ARIPIPRAZOLE

Adolescents: 2 mg PO daily for 2 days, 

then 5 mg PO daily for 2 days, 

then 10 mg PO daily. 

May be further increased in 5 mg increments at weekly or greater intervals to maximum of 30 mg PO daily. 

Children >6 years old/Adolescents:

2 mg PO daily for 7 days, 

then increase to 5 mg PO daily.

May be further increased in 5 mg increments at weekly or greater interval to maximum of 15 mg PO daily.

Tourette's Syndrome/Tic Disorder:
Children >6 years old/Adolescents:
<50 kg: 2 mg PO daily for 2 days, then 5 mg PO daily. May be further increased to 10 mg PO daily for inadequate symptom control.
>50 kg: 2 mg PO daily for 2 days, then 5 mg PO daily for 5 days, then 10 mg PO daily.  May be further increased to 20 mg PO daily in weekly increments of 5 mg/day for inadequate symptom control.

tablet: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg

(not stocked at BCCH: 30 mg)

(not stocked at BCCH: long-acting IM injection (Abilify Maintena 300 mg, 400 mg)

Considered a third generation antipsychotic, due to partial D2 receptor agonism.

Used for treatment of psychosis, agitation, aggression, bipolar disorder, disruptive behaviour, irritability of autism and tic disorders.

Adverse effects include somnolence, increased appetite, increased AST/ALT, extrapyramidal effects, lowered seizure threshold, akathisia. 

Concomitant administration of fluoxetine (or other strong CYP 2D6 inhibitors) with or without use of CYP 3A4 inhibitors may increase aripiprazole plasma concentration. Dosage reduction of aripiprazole should be considered.

Oral dispersible tablets, liquid and short-acting injection formulations are not available in Canada (USA only)

Risk of metabolic abnormalities (including weight gain, hyperglycemia and lipid abnormalities). Baseline & periodic assessment of height, weight, waist circumference, blood pressure, fasting glucose & lipid profile recommended for all patients. Refer to www.camesaguideline.org for more information.